Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table

Ramsay et al estimate that 4.8% of the UK population aged 35-69 years may be candidates for secondary prevention of coronary heart disease (CHD) by statin treatment. This treatment might reasonably be targeted at a CHD event risk of 3% per year.

Saved in:
Bibliographic Details
Published inThe Lancet (British edition) Vol. 348; no. 9024; pp. 387 - 388
Main Authors Ramsay, LE, Haq, IU, Jackson, PR, Yeo, WW, Pickin, DM, Payne, JN
Format Journal Article
LanguageEnglish
Published London Elsevier Ltd 10.08.1996
Lancet
Elsevier Limited
Subjects
Adult
Aged
Biological and medical sciences
Cardiovascular disease
Cardiovascular diseases
Coronary Disease - prevention & control
Drug therapy
Female
General and cellular metabolism. Vitamins
Health risk assessment
Humans
Hypolipidemic Agents - therapeutic use
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Prevention
Primary Prevention - methods
Risk
United Kingdom > UK
Human
Prevention
Chemotherapy
Indication
Oral administration
Cardiovascular disease
Adult
Coronary heart disease
Antilipemic agent
Online AccessGet full text

Cover

More Information
Summary:Ramsay et al estimate that 4.8% of the UK population aged 35-69 years may be candidates for secondary prevention of coronary heart disease (CHD) by statin treatment. This treatment might reasonably be targeted at a CHD event risk of 3% per year.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(96)05516-X